Vertex appoints Nancy Thornberry to board of directors

VERTEX PHARMACEUTICALS INC / MA

Nancy Thornberry, former CEO of Kallyope and ex-Merck executive, joins the board effective December 5, 2023.
Board size increased from 10 to 11 members with Thornberry's appointment.
Thornberry received a $400,000 restricted stock unit award vesting in December 2024.
No related party transactions or arrangements with any other persons were disclosed.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Nancy Thornberry

member of the board of directors

VRTX · VERTEX PHARMACEUTICALS INC / MA

Effective: 2023-12-05
Filed: December 5, 2023, 6:59 PM ET

On December 5, 2023, Nancy Thornberry was appointed as a new member of the board of directors (the “Board”) of Vertex Pharmaceuticals Incorporated (the “Company”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Nancy Thornberry was appointed as member of the board of directors at VERTEX PHARMACEUTICALS INC / MA.

Action: appointed
Role: member of the board of directors

Exact text from the filing

On December 5, 2023, Nancy Thornberry was appointed as a new member of the board of directors (the “Board”) of Vertex Pharmaceuticals Incorporated (the “Company”).

View on SEC.gov

VERTEX PHARMACEUTICALS INC / MA filing history →

Source: SEC EDGAR

accession 0000875320-23-000047

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.